$LGND News

Insider Unloading: Octavio Espinoza Sells Options, Realizes $307K

RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $262

Ligand Pharmaceuticals Q1 Earnings Call Highlights

Ligand Pharmaceuticals (NASDAQ:LGND) Shares Fall on Q1 Revenue and EPS Miss

Ligand Reports First Quarter 2026 Financial Results

Ligand Pharmaceuticals Affirms FY2026 Adj EPS Guidance of $8.50-$9.50 vs $9.13 Est; Affirms FY2026 Sales Guidance of $270.000M-$310.000M vs $281.535M Est

Ligand Pharmaceuticals Q1 Adj. EPS $1.63 Misses $1.82 Estimate, Sales $51.722M Miss $58.696M Estimate

Orchestra BioMed Receives $15M Payment From Ligand Pharma Under Previously Disclosed Revenue Participation Right Purchase And Sale Agreement

Ligand to Participate in May Investor Conferences

HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $289

LGND: XOMA Buy Adds 100+ Assets

RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $252

Ligand Pharmaceuticals to Buy XOMA Royalty for $39/Share, Lifts 2026 Guidance and EPS Outlook

Ligand Pharmaceuticals Incorporated (LGND) XOMA Royalty Corporation - M&A Call - Slideshow

Ligand Pharmaceuticals buying Xoma Royalty for $739 million

Earlier Monday, Ligand Pharmaceuticals Raises FY2026 Adj EPS Guidance from $8.00-$9.00 to $8.50-$9.50 vs $9.40 Est; Raises FY2026 Sales Guidance from $245M-$285M to $270M-$310M vs $266.714M Est

Ligand Pharmaceuticals Incorporated (LGND) M&A Call Transcript

Ligand to Report First Quarter 2026 Financial Results on May 7, 2026

Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $282

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS